Zhitong Finance App News, Zhixiang Jintai (688443.SH) issued an announcement. Recently, the company's phase III clinical trial of the indications for chronic sinusitis with nasal polyps reached the main endpoint indicators. The company submitted a new drug marketing application for this indication to the National Drug Administration (NMPA) Drug Evaluation Center (CDE) and was accepted.

Teliximab injection (GR1802 injection) is a recombinant all-human anti-IL-4Rα monoclonal antibody independently developed by the company. The target of action is IL-4Rα. Telicibimab injection can specifically bind human IL-4Rα on the cell surface, block the binding of IL-4, IL-13 and IL-4Rα, inhibit downstream STAT6 phosphorylation, and inhibit CD23 upregulation, thereby inhibiting the TH2 inflammatory response mediated by IL-4 or IL-13.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.